Experience in the treatment of metastatic and progressive renal cell cancer with sunitinib in Klaipeda University Hospital from 2008.04 till 2011.04.

Summary Renall- cell  carcinoma is the most common cancer of the kidney. Every year about 120000 new kidney cancer cases are diagnosed, in Lithuania 600-700 new cases. Sunitinib is a novel multi-tyrosine kinase inhibitor. In Klaipėda university hospital were treated 47 patients with sunitinib malate. Our data  was  compared to historic treatment with  interferon alfa . Sunitinib treatment was asssociated with a higher objective response rate. Health- related quality of life was significantly better. Only  a few patiens had progressive disease, so we can not represent objective data of progression free survival yet.